Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

11 Jul 2019

Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology

20 May 2019

HOOKIPA reported recent business highlights & financial results for the first...

8 May 2019

HOOKIPA achieved a further research milestone in its collaboration and license...

25 Apr 2019

David R. Kaufman, Chief Medical Officer (CMO) of The Bill & Melinda Gates...

18 Apr 2019

New York, US and Vienna, Austria, April 17, 2019 - HOOKIPA Pharma Inc....

26 Feb 2019

The investment was led by Redmile Group with participation of additional new...

all news

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

Our Mission

News

HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial...

HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent...

HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement...

HOOKIPA Appoints David R. Kaufman to its Board of Directors

HOOKIPA Pharma Announces Pricing of Initial Public Offering

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

Our Pipeline

Careers